1 - Title Slide 2 - Endocrinology Consultant 3 - Relevant Financial Disclosures 4 - Learning Objectives 5 - Signs of Hyperthyroidism 6 - Thyroid Abnormality 7 - Symptoms 8 - Hyperthyroid vs. Euthyroid 9 - Smoking Exacerbation 10 - Edema and Fibrosis 11 - IgG antibody 12 - Pathogenesis of TED 13 - Orbitopathy 14 - Not TED 15 - Early Signs 16 - Lissamine Green 17 - Soft Tissue Involvement 18 - Superior Limbic Keratoconjunctivitis 19 - Lid Retraction 20 - Signs with Lid Retraction 21 - von GRAEFE sign 22 - Kocher Sign 23 - Proptosis 24 - Cause & Effects 25 - Exophthalmos 26 - Degree of Proptosis 27 - Measurements 28 - Shallow Orbits 29 - Diplopia 30 - Muscle Involvement 31 - Muscle Imaging 32 - Up Gaze Restriction 33 - Optic Neuropathy 34 - Optic Neuropathy Predictors 35 - Visual Acuity Checks 36 - Increased IOP 37 - Rundle's Curve 38 - What to Call It 39 - CAS 40 - Mild Disease 41 - Treatment 42 - QOL and Mental Health 43 - Ophthalmopathy Treatment 44 - Medical vs Surgical 45 - Surgery 46 - Therapeutic Options 47 - Steroids 48 - Steroids Pros/Cons 49 - Mycophenolate 50 - Rituximab 51 - Tocilizumab 52 - Orbital Radiation 53 - Teprotumumab 54 - OPTIC Trial 55 - OPTIC Trial (Cont.) 56 - Teprotumumab for TED 57 - Proptosis Reduction 58 - Diplopia Improvement 59 - EOM Shrinkage 60 - Side Effects 61 - IBD and Pregnancy 62 - IV Administration 63 - Teprotumumab CTED 64 - Thrive-2 Trial 65 - Phase 2 Trial 66 - Phase 3 Studies 67 - Subcutaneous Trial 68 - Lids Oral Trial 69 - Team 70 - Summary 71 - Thank You